In a meta-analysis, including three randomized controlled trials with a total of 1,831 patients, results showed that initiation of SGLT2 inhibitors in patients did not increase the AKI [OR: 0.76; 95% CI: (0.50, 1.16)] (20). This evidence concerns the gene SLC5A2 and acute kidney injury.